Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov 22;83(11):1480–1487. doi: 10.1054/bjoc.2000.1461

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

J-Y Pierga 1, E Mouret 2, V Diéras 1, V Laurence 1, P Beuzeboc 1, T Dorval 1, T Palangié 1, M Jouve 1, A Vincent-Salomon 1, S Scholl 1, J-M Extra 1, B Asselain 2, P Pouillart 1
PMCID: PMC2363409  PMID: 11076657

Abstract

Neoadjuvant chemotherapy is able to reduce the size of the majority of breast tumours and down-stage axillary-node status. The aim of this study was to assess the prognostic value of persistent node involvement after neoadjuvant chemotherapy. A total of 488 patients with T2–T3, N0–N1 breast cancer treated by neoadjuvant chemotherapy followed by tumour excision and axillary lymph-node dissection between 1981 and 1992 were selected from the Institut Curie database. Median follow-up was 7 years. Overall objective response rate before local treatment was 52% and breast tumour size was reduced in 83% of patients. No pathologic nodal involvement was observed in 46.5% of patients. Patients with ≥ eight positive nodes had a very poor median disease-free survival of only 20 months. Their 10-year disease-free survival rate was 7%, while the 10-year disease-free survival rate for patients with no node involvement was 64%. Median survival for patients with ≥ eight nodes positive was 48 months and the 10-year survival rate was 26% (P < 0.0001). On multivariate analysis, outcome was strongly correlated with pathological nodal status, tumour grade, hormonal receptor status and clinical response of the tumour. In conclusion, patients with extensive nodal involvement after neoadjuvant chemotherapy have a very poor outcome. Second-line treatment should be considered in this population. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords: neoadjuvant chemotherapy, breast cancer, pathological nodal metastasis

Full Text

The Full Text of this article is available as a PDF (82.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhalla K., Harris W. B. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol. 1998 Apr;25(2 Suppl 3):19–24. [PubMed] [Google Scholar]
  2. Bonadonna G., Valagussa P., Brambilla C., Ferrari L., Moliterni A., Terenziani M., Zambetti M. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998 Jan;16(1):93–100. doi: 10.1200/JCO.1998.16.1.93. [DOI] [PubMed] [Google Scholar]
  3. Botti C., Vici P., Lopez M., Scinto A. F., Cognetti F., Cavaliere R. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg. 1995 Sep;181(3):202–208. [PubMed] [Google Scholar]
  4. Cameron D. A., Anderson E. D., Levack P., Hawkins R. A., Anderson T. J., Leonard R. C., Forrest A. P., Chetty U. Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 1997;76(8):1099–1105. doi: 10.1038/bjc.1997.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carter C. L., Allen C., Henson D. E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989 Jan 1;63(1):181–187. doi: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  6. Colleoni M., Orvieto E., Nolé F., Orlando L., Minchella I., Viale G., Peruzzotti G., Robertson C., Noberasco C., Galimberti V. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer. 1999 Apr;35(4):574–579. doi: 10.1016/s0959-8049(99)00005-2. [DOI] [PubMed] [Google Scholar]
  7. Costa S. D., von Minckwitz G., Raab G., Blohmer J. U., Dresel V., Eidtmann H., Hilfrich J., Jackisch C., Merkle E., Gademann G. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 9):24–31. [PubMed] [Google Scholar]
  8. Ellis P., Smith I., Ashley S., Walsh G., Ebbs S., Baum M., Sacks N., McKinna J. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 1998 Jan;16(1):107–114. doi: 10.1200/JCO.1998.16.1.107. [DOI] [PubMed] [Google Scholar]
  9. Fisher B., Bauer M., Wickerham D. L., Redmond C. K., Fisher E. R., Cruz A. B., Foster R., Gardner B., Lerner H., Margolese R. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983 Nov 1;52(9):1551–1557. doi: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  10. Fisher B., Brown A., Mamounas E., Wieand S., Robidoux A., Margolese R. G., Cruz A. B., Jr, Fisher E. R., Wickerham D. L., Wolmark N. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997 Jul;15(7):2483–2493. doi: 10.1200/JCO.1997.15.7.2483. [DOI] [PubMed] [Google Scholar]
  11. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E. R., Wickerham D. L., Begovic M., DeCillis A., Robidoux A. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998 Aug;16(8):2672–2685. doi: 10.1200/JCO.1998.16.8.2672. [DOI] [PubMed] [Google Scholar]
  12. Gardin G., Rosso R., Campora E., Repetto L., Naso C., Canavese G., Catturich A., Corvò R., Guenzi M., Pronzato P. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer. 1995;31A(9):1428–1433. doi: 10.1016/0959-8049(95)00199-s. [DOI] [PubMed] [Google Scholar]
  13. Haagensen C. D. Treatment of curable carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):975–980. doi: 10.1016/0360-3016(77)90198-5. [DOI] [PubMed] [Google Scholar]
  14. Jain V., Landry M., Levine E. A. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg. 1996 Feb;62(2):162–165. [PubMed] [Google Scholar]
  15. Krag D., Weaver D., Ashikaga T., Moffat F., Klimberg V. S., Shriver C., Feldman S., Kusminsky R., Gadd M., Kuhn J. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med. 1998 Oct 1;339(14):941–946. doi: 10.1056/NEJM199810013391401. [DOI] [PubMed] [Google Scholar]
  16. Kuerer H. M., Newman L. A., Buzdar A. U., Hunt K. K., Dhingra K., Buchholz T. A., Binkley S. M., Ames F. C., Feig B. W., Ross M. I. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec;176(6):502–509. doi: 10.1016/s0002-9610(98)00253-0. [DOI] [PubMed] [Google Scholar]
  17. Kuerer H. M., Newman L. A., Smith T. L., Ames F. C., Hunt K. K., Dhingra K., Theriault R. L., Singh G., Binkley S. M., Sneige N. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb;17(2):460–469. doi: 10.1200/JCO.1999.17.2.460. [DOI] [PubMed] [Google Scholar]
  18. Kuerer H. M., Sahin A. A., Hunt K. K., Newman L. A., Breslin T. M., Ames F. C., Ross M. I., Buzdar A. U., Hortobagyi G. N., Singletary S. E. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul;230(1):72–78. doi: 10.1097/00000658-199907000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. MacGrogan G., Mauriac L., Durand M., Bonichon F., Trojani M., de Mascarel I., Coindre J. M. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 1996 Nov;74(9):1458–1465. doi: 10.1038/bjc.1996.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Machiavelli M. R., Romero A. O., Pérez J. E., Lacava J. A., Domínguez M. E., Rodríguez R., Barbieri M. R., Romero Acuña L. A., Romero Acuña J. M., Langhi M. J. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am. 1998 Mar-Apr;4(2):125–131. [PubMed] [Google Scholar]
  21. Makris A., Powles T. J., Dowsett M., Osborne C. K., Trott P. A., Fernando I. N., Ashley S. E., Ormerod M. G., Titley J. C., Gregory R. K. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr;3(4):593–600. [PubMed] [Google Scholar]
  22. Mamounas E. P. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol. 1998 Apr;25(2 Suppl 3):31–35. [PubMed] [Google Scholar]
  23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  24. Mauriac L., MacGrogan G., Avril A., Durand M., Floquet A., Debled M., Dilhuydy J. M., Bonichon F. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999 Jan;10(1):47–52. doi: 10.1023/a:1008337009350. [DOI] [PubMed] [Google Scholar]
  25. McCready D. R., Hortobagyi G. N., Kau S. W., Smith T. L., Buzdar A. U., Balch C. M. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989 Jan;124(1):21–25. doi: 10.1001/archsurg.1989.01410010027005. [DOI] [PubMed] [Google Scholar]
  26. Nemoto T., Vana J., Bedwani R. N., Baker H. W., McGregor F. H., Murphy G. P. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980 Jun 15;45(12):2917–2924. doi: 10.1002/1097-0142(19800615)45:12<2917::aid-cncr2820451203>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  27. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–655. [PubMed] [Google Scholar]
  28. Powles T. J., Hickish T. F., Makris A., Ashley S. E., O'Brien M. E., Tidy V. A., Casey S., Nash A. G., Sacks N., Cosgrove D. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995 Mar;13(3):547–552. doi: 10.1200/JCO.1995.13.3.547. [DOI] [PubMed] [Google Scholar]
  29. Pusztai L., Hortobagyi G. N. Discouraging news for high-dose chemotherapy in high-risk breast cancer. Lancet. 1998 Aug 15;352(9127):501–502. doi: 10.1016/S0140-6736(05)79310-7. [DOI] [PubMed] [Google Scholar]
  30. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelénat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989 Sep 20;81(18):1383–1387. doi: 10.1093/jnci/81.18.1383. [DOI] [PubMed] [Google Scholar]
  31. Remvikos Y., Mosseri V., Zajdela A., Fourquet A., Durand J. C., Pouillart P., Magdelénat H. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci. 1993 Nov 30;698:193–203. doi: 10.1111/j.1749-6632.1993.tb17209.x. [DOI] [PubMed] [Google Scholar]
  32. Sataloff D. M., Mason B. A., Prestipino A. J., Seinige U. L., Lieber C. P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995 Mar;180(3):297–306. [PubMed] [Google Scholar]
  33. Scholl S. M., Fourquet A., Asselain B., Pierga J. Y., Vilcoq J. R., Durand J. C., Dorval T., Palangié T., Jouve M., Beuzeboc P. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30A(5):645–652. doi: 10.1016/0959-8049(94)90537-1. [DOI] [PubMed] [Google Scholar]
  34. Scholl S. M., Pierga J. Y., Asselain B., Beuzeboc P., Dorval T., Garcia-Giralt E., Jouve M., Palangié T., Remvikos Y., Durand J. C. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995 Nov;31A(12):1969–1975. doi: 10.1016/0959-8049(95)00454-8. [DOI] [PubMed] [Google Scholar]
  35. Semiglazov V. F., Topuzov E. E., Bavli J. L., Moiseyenko V. M., Ivanova O. A., Seleznev I. K., Orlov A. A., Barash N. Y., Golubeva O. M., Chepic O. F. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994 Sep;5(7):591–595. doi: 10.1093/oxfordjournals.annonc.a058929. [DOI] [PubMed] [Google Scholar]
  36. Smith I. E., Walsh G., Jones A., Prendiville J., Johnston S., Gusterson B., Ramage F., Robertshaw H., Sacks N., Ebbs S. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995 Feb;13(2):424–429. doi: 10.1200/JCO.1995.13.2.424. [DOI] [PubMed] [Google Scholar]
  37. Valagussa P., Bonadonna G., Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978 Mar;41(3):1170–1178. doi: 10.1002/1097-0142(197803)41:3<1170::aid-cncr2820410355>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES